Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Next Previous
Trial Profile

Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms AtezoTRIBE

    • Most Recent Events

    • 24 Oct 2023 Results assessing the predictive role of immune phenotypes (IPs) and Inflamed Score (IS), as assessed by means of Lunit SCOPE IO, an artificial intelligence (AI)-powered whole-slide images (WSI) analyzer of tumor infiltrating lymphocytes, presented at the 48th European Society for Medical Oncology Congress.
    • 11 Oct 2023 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2023 Results determining the percentage of genomic LOH and the presence of pathogenetic mutations in HRR related genes in archival chemo-naive tumor tissues of mCRC patients included in a real world registry and in the Atezo TRIBE (NCT03721653) and AVETRIC (NCT04513951) studies, presented at the 25th World Congress on Gastrointestinal Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top